PUBLIC COMPANY
save$BMRNBIOMARIN PHARMACEUTICAL INC
$BMRN68.84-0.06%Novato, CA, USupdated 3h ago
community read0 votes
pipeline
7
marketed
6
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(7)
pipeline depth7 products
1Phase 36Marketed
Marketed
cerliponase alfa
Batten Disease
Marketedelosulfase alfa
Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome )
Marketedgalsulfase
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome )
Marketedpegvaliase
Hyperphenylalaninemia
Marketedvaloctocogene roxaparvovec
Hemophilia A (Factor VIII Deficiency)
Marketedvosoritide
Noonan Syndrome
Atrial natriuretic peptide receptor 2
Phase 3efmirenpase alfa
Arterial Calcification
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase3Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
- phase2Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
- —Cerliponase Alfa Observational Study in the US
- phase2A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
- phase3Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
- phase2A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
- phase4Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
- phase2A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Mar 18, 26tax coverDavis George Eric · EVP, Chief Legal Officer1,273 sh
- Mar 17, 26tax coverHardy Alexander · Chief Executive Officer4,252 sh
- Mar 17, 26tax coverMueller Brian · EVP, Chief Financial Officer2,117 sh
- Mar 17, 26tax coverGuyer Charles Greg · EVP, Chief Technical Officer1,693 sh
- Mar 17, 26tax coverFriberg Gregory R · EVP, Chief R&D Officer1,629 sh
- Mar 17, 26tax coverHubbard Cristin · EVP, Chief Commercial Officer1,245 sh
🐶 Hiring Signal
News
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 4h ago
- BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indicationBioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.biospace · 1d ago
- BioMarin axes $270M rare disease asset after missing phase 3 endpointBioMarin Pharmaceutical has ended development of BMN 401 in all indications months after reporting mixed phase 3 data on the rare disease prospect.fiercebiotech · 4d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 5d ago
- Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharmaTakeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac.biospace · 26d ago
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.biopharma_dive · 2mo ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that